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Basal Versus Sliding-Scale Regular Insulin
in Hospitalized Patients With
Hyperglycemia During Enteral Nutrition
Therapy
A
large number of hospitalized pa-
tients are in a catabolic state, with
resultant increased caloric and pro-
tein needs. In such patients, inadequate
oralintakecanleadtoundernutritionin8
to 12 days (1). A collaborative study in-
volving nutrition screening of 3,047 pa-
tients at admission to 33 hospitals
reported that more than 50% of hospital-
izedpatientsweremalnourished(2).Mal-
nutrition is seen in several patient groups
with diabetes, especially in the elderly (3)
and those with complications such as re-
nal failure or neurological dysfunctions
(4).Nutritionguidelinesstatethatanypa-
tient unable to consume adequate nutri-
ents orally (60% nutrition needs) for at
least 5 days in the critically ill or 7 to 14
daysinthegeneralpopulationshouldbea
candidate for specialized nutrition sup-
port (5,6). Delayed feeding, resulting in
malnutrition, may increase the risk of
hospital complications (relative risk
1.60), higher mortality (12.4 vs. 4.7% in
the well-nourished patients [relative risk
2.63]), and longer hospital stay (16.7 
24 vs. 10.1  12 days in the nourished
patients) and may increase hospital costs
by 308% (7). A recent meta-analysis re-
ported that providing early versus de-
layed nutrition support results in lower
infectious complications and length of
hospital stay (8). Nutritional support via
enteral or parenteral nutrition in mal-
nourished patients may prevent such
complications. Although both forms of
nutrition support have been shown to be
successfulinpreventingtheeffectsofstar-
vation and malnutrition, oral or enteral
nutrition is preferable to parenteral nutri-
tion in clinical practice (9,10). Advan-
tages of enteral feeding over parenteral
nutrition include lower costs, avoidance
of central catheter–related complications,
its more physiological route, and its tro-
phic effect on gastrointestinal cells (11).
Standard enteral formulas reﬂect the
reference values for macro- and micronu-
trients for a healthy population. Most
standard formulas contain whole protein,
lipid in the form of long-chain triglycer-
ides, and ﬁber. Most diabetes-speciﬁc en-
teral formulas comply with this rule in
two different ways: standard formulas
provide low amounts of lipids (30% of
total calories) combined with a high sup-
ply of complex carbohydrates (55–60%
of total calories), most of these being
starch, possibly containing fructose;
newer diabetic formulas have replaced
part of carbohydrates with monounsatu-
rated fatty acids (up to 35% of total calo-
ries) and may include dietary ﬁber (5). A
number of outpatient and inpatient stud-
ies in subjects with type 2 diabetes have
reported better glycemic control (lower
mean, fasting, and/or postprandial glu-
cose levels), a trend toward decreased
A1C levels, and lower insulin require-
ments with low-carbohydrate high–
monounsaturated fatty acid (LCHM)
formulas compared with standard high-
carbohydrate formulas (12,13). Based
on these results, it is generally accepted
that newer diabetic enteral formulas
(LCHM) are preferable to standard high-
carbohydrate formulas in hospitalized
patients with type 1 and type 2 diabetes
(4,5).
Hyperglycemia is a common compli-
cation of enteral nutrition therapy re-
portedinuptoone-thirdofadultpatients
in the hospital (14) and in up to one-half
of elderly patients in long-term services
(15). Increasing evidence indicates that
the development of hyperglycemia dur-
ing acute medical or surgical illness is not
a physiological or benign condition but is
a marker of poor clinical outcome and
mortality(16,17).Insulin,giveneitherin-
travenously as a continuous infusion or
subcutaneously, is the most effective
agent for immediate control of hypergly-
cemia in the hospital. In the critical care
setting, continuous insulin infusion has
been shown to be effective in achieving
glycemiccontrol(17,18).Ingeneralmed-
icine and surgery services, however, few
studies have focused on the optimal man-
agement of hyperglycemia during enteral
nutrition therapy. Several clinical reviews
and small uncontrolled studies recom-
mend a variety of subcutaneous regimens
including the administration of regular
insulin(every4–6h),NPHinsulin(every
8–12 h), or once- or twice-daily insulin
glargine (17,19).
In this issue of Diabetes Care, Koryt-
kowski et al. (20) report the ﬁrst random-
ized study comparing subcutaneous
insulin regimens in non–critically ill
adult patients with type 2 diabetes receiv-
ing enteral nutrition therapy. Fifty pa-
tientswithorwithoutahistoryofdiabetes
andwithtwoormorebloodglucoselevels
130 mg/dl (7.2 mmol/l) were random-
ized to receive sliding-scale regular insu-
lin (SSRI) (n  25) or glargine insulin
once daily (n  25). NPH insulin was
addedintheSSRIgroupforpersistenthy-
perglycemia (more than two blood glu-
coselevels180mg/dl).Insuchpatients,
NPH insulin was given every 12 h at a
starting dose equal to 50% of prior-day
total regular insulin dose. Subjects in the
glargine group who were insulin naïve
were started at an evening dose of 10
units/day, while those already receiving
basal insulin were changed or continued
at the same number of units per day. In
addition, supplemental SSRI was admin-
istered every 4–6 h for any blood glucose
level 130 mg/dl (7.1 mmol/l) in both
groups. To prevent hypoglycemia, dex-
trose-containing intravenous ﬂuids were
initiated within 30 min of any unantici-
pated discontinuation of enteral nutrition
if the dose of basal insulin had been given
in the prior 12-h time period. The glyce-
mic target goal in both groups was to
achieve glucose levels between 100 and
180 mg/dl (5.6 and 10 mmol/l).
Mean daily blood glucose as well as
mean daily peak and nadir blood glucose
values were similar in the SSRI and
glargine groups. In the SSRI group, 13 of
25 patients (52%) remained on regular
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the target range and 12 patients (48%)
required the addition of NPH insulin
twice daily because of persistent hyper-
glycemiaduringthehospitalstay.Patients
who failed SSRI treatment and required
the addition of NPH insulin had a higher
mean baseline blood glucose level (203
vs. 150 mg/dl) and were more likely to
have a previous history of diabetes (67 vs.
46%). Total daily insulin dose (27
units/day) and the number of insulin
units per body weight (0.33 units/kg)
were similar between treatment groups.
There were no group differences in
the overall frequency of hypoglycemia
(1.34.1vs.1.11.8%;P0.35)orin
the percentage of patient days with hypo-
glycemia (4.8 vs. 2.7%; P  0.34). Four
patients in the glargine group and seven
patients in the SSRI group had a blood
glucose level 70 mg/dl. Six of the seven
episodes of hypoglycemia in the SSRI
groupoccurredinpatientsreceivingNPH
insulin.
Despite the small number of patients,
this study provides a valuable guide for in-
sulin administration in patients, with and
without a history of diabetes, who develop
hyperglycemia during enteral nutrition
therapy. More prospective randomized
studies are clearly needed in order to deter-
minetheoptimalmanagementofhypergly-
cemia in hospitalized patients receiving
nutrition support. Such studies should
include larger numbers of medical and
surgicalpatientsinintensivecareunitand
non–intensive care unit settings. In addi-
tion, clinical trials are needed to deter-
mine the efﬁcacy and safety of glycemic
control in diabetic subjects receiving in-
travenous parenteral nutrition. The rate
of hyperglycemia in patients receiving
parenteral nutrition is higher compared
with enteral nutrition due to the higher
glucose load, which may lead to an in-
creased number of complications and
hospital mortality (21,22). Prospective
randomized trials in patients with critical
illness have shown that aggressive glyce-
mic control can reduce short- and long-
term mortality, multiorgan failure, and
systemicinfections(23,24);however,itis
not clear if intensiﬁed insulin therapy in
patients with parenteral nutrition–
induced hyperglycemia will result in im-
proved clinical outcomes and mortality
reduction.
In summary, the study by Koryt-
kowski et al. provides important clinical
information. First, this study indicates
that similar levels of glycemic control
were achieved in the SSRI and glargine
groups. Treatment with SSRI alone was
effective in maintaining glycemic control
in about two-thirds of nondiabetic pa-
tients with mild hyperglycemia; however,
two-thirds of patients with a history of
diabetes in the SSRI group required the
addition of NPH insulin twice daily be-
cause of persistent hyperglycemia. Sec-
ond, in patients with known diabetes,
earlytreatmentwithbasalinsulinglargine
or with NPH insulin is effective and safe
and should be preferred over SSRI alone
inthemanagementofhyperglycemiadur-
ing enteral nutrition therapy. These re-
sultsareinagreementwiththosereported
in recent randomized control studies in
hospitalized patients with type 2 diabetes
(25–27). Finally, the results of this study
indicate that implementing standardized
nutritional support orders together with
basal insulin order sets are key interven-
tions that might reduce complications as-
sociated with severe hyperglycemia and
hypoglycemia in hospitalized patients.
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